意大利慢性髓性白血病网络一线治疗转换风险因素与原因队列研究
该前瞻性队列分析1662例CML患者,一线伊马替尼占50.5%、尼洛替尼29.5%、达沙替尼20.0%。492例(29.6%)需二线治疗,47.1%因耐药、35.8%因不耐受。2年耐药风险伊马替尼18.3%、达沙替尼8.4%、尼洛替尼6.8%;中/高危ELTS及年轻患者转换风险更高,达沙替尼不耐受风险较高。
要点
- 2年耐药风险:伊马替尼18.3%,达沙替尼8.4%(sHR 0.32),尼洛替尼6.8%(sHR 0.29)。
- 中危ELTS sHR 1.95、高危3.19,年龄每增1岁转换风险降低(sHR 0.97)。
- 2年不耐受风险:伊马替尼8.5%,达沙替尼12.4%(sHR 2.55),尼洛替尼5.2%。
核心结论
- 年轻、伊马替尼及中/高危ELTS患者因耐药转换治疗的时间更短。
- 初始达沙替尼治疗者因不耐受转换的风险更高。
研究设计与样本
- 意大利CML网络前瞻性队列研究,纳入1662例患者。
- 采用Fine和Gray多变量模型估计亚风险比(sHR)。
主要发现
- 492例(29.6%)需二线治疗,其中232例(47.1%)因耐药、176例(35.8%)因不耐受。
- 2年耐药风险:伊马替尼18.3%,达沙替尼8.4%(sHR 0.32;95%CI 0.21-0.49),尼洛替尼6.8%(sHR 0.29;95%CI 0.19-0.42)。
- 转换风险随ELTS中危(sHR 1.95;95%CI 1.40-2.72)和高危(sHR 3.19;95%CI 2.10-4.83)增加,随年龄增长降低(每岁sHR 0.97;P<0.0001)。
- 2年不耐受风险:伊马替尼8.5%,达沙替尼12.4%(sHR 2.55;95%CI 1.73-3.75),尼洛替尼5.2%(sHR 1.04;95%CI 0.65-1.65)。
- 3年转为三线治疗比例:伊马替尼8%,达沙替尼5%,尼洛替尼4%。
临床怎么用
- 对年轻、中/高危ELTS患者加强耐药监测,尽早识别需转换治疗者。
- 初始达沙替尼者需关注不耐受风险,及时评估换药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Identifying chronic myeloid leukaemia (CML) patients at risk of therapeutic switch remains debated. We analysed the cumulative risk of treatment change in the CML Italian network prospective cohort based on first-line tyrosine kinase inhibitors and patient characteristics. Sub-hazard ratios (sHRs) were estimated using Fine and Gray multivariable models. Among 1662 patients, initial treatment consisted of imatinib for 840 (50.5%), nilotinib for 490 (29.5%) and dasatinib for 332 (20.0%). Subsequently, 492 patients (29.6%) required second-line therapy, with 232 (47.1%) switching due to resistance and 176 (35.8%) due to intolerance. At 2 years, the risk of resistance was 18.3% for imatinib, 8.4% for dasatinib (sHR = 0.32; 95% confidence interval 0.21-0.49) and 6.8% for nilotinib (0.29; 0.19-0.42). The risk of switching increased in intermediate (1.95; 1.40-2.72) and high Eutos long term survival (ELTS) risk (3.19; 2.10-4.83) but was reduced with older age (0.97 per year; p < 0.0001). Intolerance at 2 years was 8.5% for imatinib, 12.4% for dasatinib (2.55; 1.73-3.75) and 5.2% for nilotinib (1.04; 0.65-1.65). Switching to a third-line therapy at 3 years was 8% for imatinib, 5% for dasatinib and 4% for nilotinib. The results showed that the time to first treatment switch for resistance is shorter for younger patients, for imatinib and for intermediate/high ELTS risks. The risk of switching for intolerance is higher for patients initially treated with dasatinib.
引用
- Breccia M, Giai V, Rosso T, et al. Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study. Br J Haematol. 2026. PMID: 41521026. doi:10.1111/bjh.70332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。